Pharos iBio Co., Ltd. Stock Price

KOSDAQ:A388870 Community·₩124.9b Market Cap

0 Narratives written by author
0 Comments on narratives written by author
0 Fair Values set on narratives written by author

Create a narrative

A388870 Share Price Performance

₩0

-6030.00 (-100.00%)

₩0

-6030.00 (-100.00%)

₩0

Thu, 2 Apr 26

Share Pricen/a

A388870 Community Narratives

There are no narratives available yet.

Create a narrative

There are no community narratives available.

Trending Discussion

Snowflake Analysis

Flawless balance sheet with low risk.

3 Risks

0 Rewards

View Full Analysis

Pharos iBio Co., Ltd. Key Details

Last Reported Earnings

Dec 31, 2025

Next Reporting Earnings

n/a

: -830.89
: 0%
: 0%
: 55.5%

View Full Analysis

About A388870

Founded: 2016
Employees: n/a
CEO: Jeong Hyeok Yoon
WebsiteView website: www.pharosibio.com

Pharos iBio Co., Ltd. engages in the development of treatments for rare and refractory diseases using AI based drug development platform in South Korea. It develops PHI-101-AML that is in phase 1 clinical trial for the treatment of refractory/recurrent acute myelogenous leukemia (AML); PHI-101-OC that is in phase 1 clinical trial for the treatment of recurrent ovarian cancer; PHI-501 for refractory solid cancer; PHI-301 for the treatment of refractory lung cancer; and PHI-601 for the treatment of menin inhibitor. The company was founded in 2016 and is headquartered in Anyang-Si, South Korea.